Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Milestone Pharmaceuticals ( (MIST) ) is now available.
On January 12, 2026, Milestone Pharmaceuticals closed a previously arranged royalty financing transaction under a Royalty Purchase Agreement with RTW Royalty I DAC, an affiliate of RTW Investments, whereby funds managed by RTW paid $75 million to acquire a royalty interest in future tiered quarterly royalty payments on U.S. net product sales of etripamil. The closing of this sale, contingent on prior U.S. Food and Drug Administration approval of etripamil, provided Milestone with significant non-dilutive capital in exchange for a portion of future U.S. sales, potentially strengthening its financial position while shifting some long-term revenue upside to RTW.
The most recent analyst rating on (MIST) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Neutral.
The score is held down primarily by weak financial performance (no revenue, large and widening losses, and accelerating cash burn alongside higher leverage). Corporate events are a major offset (FDA approval and EMA MAA acceptance), but technicals remain soft and valuation metrics provide limited support due to ongoing losses.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing etripamil, a fast-acting calcium channel blocker, for the treatment of cardiovascular conditions, with a primary market focus on the United States.
Average Trading Volume: 5,079,241
Technical Sentiment Signal: Buy
Current Market Cap: $173.7M
Find detailed analytics on MIST stock on TipRanks’ Stock Analysis page.
